Celldex Therapeutics
CLDX
CLDX
167 hedge funds and large institutions have $1.65B invested in Celldex Therapeutics in 2022 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 64 increasing their positions, 52 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
6% less capital invested
Capital invested by funds: $1.75B → $1.65B (-$104M)
7% less funds holding
Funds holding: 179 → 167 (-12)
33% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 30
Holders
167
Holding in Top 10
7
Calls
$72.7M
Puts
$39.3M
Top Buyers
| 1 | +$45.8M | |
| 2 | +$37.1M | |
| 3 | +$24.3M | |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$17.9M |
| 5 |
TLP
Tri Locum Partners
New York
|
+$13.1M |
Top Sellers
| 1 | -$28.5M | |
| 2 | -$22.1M | |
| 3 | -$18M | |
| 4 |
FAM
Fred Alger Management
New York
|
-$11.8M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10.5M |